Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia
· Delayed Price · Currency is AUD 0.615
+0.055 (9.82%)
Feb 21, 2025, 4:10 PM AEST
Paradigm Biopharmaceuticals Company Description
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia.
It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.
The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Paradigm Biopharmaceuticals Limited
| Country | Australia |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Paul Rennie |
Contact Details
Address: 500 Collins Street Melbourne, 3000 Australia | |
| Phone | 61 3 9629 5566 |
| Website | paradigmbiopharma.com |
Stock Details
| Ticker Symbol | PAR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PAR5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul John Rennie BSc, Grad Dip, MBM, MSTC | Founder, MD and Executive Chairman |
| Dr. Donna L. Skerrett M.D., MS | Chief Medical Officer |
| Abby Macnish Niven B.Com., B.Sc., C.F.A. | Company Secretary and Chief Financial Officer |
| Dr. Ravi Krishnan | Chief Scientific Officer |
| Simon White | Director of Investor Relations |
| Dr. Michael Imperiale | Global Head of Drug Safety and MPS |
| Beverley Huttmann | Commercial Head |
| Michelle Coffey | Global Head of Regulatory Affairs |
| Dr. Mukesh Ahuja | Global Clinical Head of OA |